8-K: Orgenesis Inc. Faces Nasdaq Delisting After Restatement Reveals Stockholders' Deficit

Orgenesis Inc. received a delisting notice from Nasdaq after restating its financials, revealing a stockholders' deficit and failing to meet minimum equity requirements.

Summary

• Orgenesis Inc. received a notice from Nasdaq on April 17, 2024, stating that the company no longer meets the minimum requirements for continued listing.
• This notice was triggered by a restatement of the company's financial statements, which changed the reported stockholders' equity from $12,397,000 to a deficit of ($15,372,000) for the period ended September 30, 2023.
• The restatement caused the company to no longer qualify for a second 180-day compliance period to regain compliance with the minimum bid price rule.
• The company also failed to meet the minimum $5,000,000 stockholders' equity requirement for initial listing and the $2,500,000 minimum for continued listing on the Nasdaq Capital Market.
• Nasdaq will delist the company's securities unless Orgenesis requests a hearing before a Nasdaq Hearings Panel.
• Orgenesis plans to request a hearing, which will temporarily halt the delisting process while the hearing is pending.
• There is no guarantee that Orgenesis will regain compliance and remain listed on Nasdaq.

Sentiment

Score: 2

Explanation: The document indicates a significant negative event with the delisting notice and the restatement of financials revealing a large deficit. The company's future on Nasdaq is uncertain, leading to a very negative sentiment.

Positives

• The company is requesting a hearing to appeal the delisting, which will temporarily halt the delisting process.
• The company's stock will remain listed on Nasdaq pending the outcome of the hearing.

Negatives

• The company received a delisting notice from Nasdaq.
• The restatement of financials resulted in a significant stockholders' deficit of ($15,372,000).
• The company failed to meet the minimum stockholders' equity requirements for both initial and continued listing on Nasdaq.
• There is no assurance that the company will regain compliance and remain listed on Nasdaq.

Risks

• The company faces the risk of being delisted from the Nasdaq Capital Market.
• There is uncertainty regarding the outcome of the hearing and whether the company can regain compliance.
• The restatement of financials indicates potential issues with the company's financial reporting.
• The company's stock price may be negatively impacted by the delisting notice and uncertainty surrounding its future on Nasdaq.

Future Outlook

The company plans to request a hearing before a Nasdaq Hearings Panel to address the deficiencies and present a plan to regain compliance. There is no assurance that the company will ultimately regain compliance and remain listed on Nasdaq.

Management Comments

• The company plans to timely request a hearing before the Panel.
• There can be no assurance that the Company will ultimately regain compliance and remain listed on Nasdaq.

Industry Context

This delisting notice highlights the challenges faced by companies that fail to maintain minimum financial standards required by stock exchanges. It is not uncommon for companies to face delisting if they fail to meet the minimum bid price or equity requirements. This situation may cause investors to be more cautious about investing in companies with weak financial positions.

Comparison to Industry Standards

• Many companies on the Nasdaq Capital Market are required to maintain a minimum bid price of $1.00 and a minimum stockholders' equity of $2.5 million to remain listed.
• Orgenesis's failure to meet these requirements is a significant deviation from the standards expected of companies listed on the Nasdaq Capital Market.
• Other companies that have faced similar delisting notices include those in the biotechnology and pharmaceutical sectors, which often have volatile stock prices and may struggle to maintain consistent profitability.
• Companies like Agenus Inc. and Cellectar Biosciences have also faced delisting warnings due to low stock prices, highlighting the challenges in the sector.

Stakeholder Impact

• Shareholders face the risk of losing their investment if the company is delisted.
• Employees may experience uncertainty about the company's future.
• Customers and suppliers may be concerned about the company's ability to continue operations.

Next Steps

• The company plans to request a hearing before a Nasdaq Hearings Panel.
• The company will present a plan to regain compliance at the hearing.
• The company will await the outcome of the hearing to determine if it will remain listed on Nasdaq.

Key Dates

Keywords

delisting, Nasdaq, stockholders' equity, restatement, compliance, hearing, financial statements, ORGS